Fig. 3
DAC and RSL3 synergistically induce ferroptosis in AML cells in vitro. (A and B) AML cells were treated with different concentrations of DAC (0.25 µM, 0.5 µM, 0.75 µM, 1.0 µM, 2.5 µM) for 48 h, RSL3 (0.025 µM, 0.05 µM, 0.075 µM, 0.1 µM, 0.25 µM) for 24 h, or their combination. CalcuSyn was used to assess the possible synergistic effects. CI < 1.0 is considered a synergistic effect. (C and D) Lipid ROS levels were measured in MOLM-13 and MV4-11 cells treated with DAC (0.5 µM) for 48 h, RSL3 (0.05 µM) for 24 h, or their combination. Representative plots (left) and statistical analysis of lipid ROS levels (right) are shown. (E–H) MDA (E and F) and GSH amounts (G and H) were measured in MOLM-13 and MV4-11 cells treated with DAC, RSL3, or DAC + RSL3 cotreatment. (I and J) The intracellular iron assay was performed by flow cytometry in MOLM-13 and MV4-11 cells treated with Ctrl, DAC, RSL3, or DAC + RSL3 cotreatment. Representative plots (left) and statistical analysis of Fe2+ levels (right) are shown. *P < 0.05; **P < 0.01; ***P < 0.001. N.S: not significant